Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending November 1, 2018. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital and voting rights data.
| Metric | Value |
|---|---|
| Issued Share Capital (as of Oct 31, 2018) | 5,375,169,306 Ordinary Shares (25 pence each) |
| Treasury Shares | 414,605,950 |
| Total Voting Rights | 4,960,563,356 |
Material Changes
The filing text does not provide a clear value or description of material changes versus the prior comparable period. It presents a static snapshot of share capital as of October 31, 2018.
Guidance, Outlook, and Risks
The filing text does not provide clear values or commentary regarding guidance, outlook, management discussion, risks, contingencies, or unusual items. The document is a regulatory notification of capital structure.
Key Facts for Investor Verification
- Verify the total number of voting rights (4,960,563,356) to determine notification thresholds under FCA rules.
- Confirm the number of shares held in Treasury (414,605,950) which are excluded from voting rights.
- Note that this filing does not contain financial performance data; refer to Form 20-F for financial results.